Dosing Variation at Initiation of Adalimumab and Etanercept is not Associated with Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry study.

Journal Article (Journal Article)

OBJECTIVE: To determine the dose-response relationship of tumor necrosis factor (TNF) inhibition in the treatment of juvenile idiopathic arthritis (JIA). METHODS: Participants of the Childhood Arthritis and Rheumatology Research Alliance Registry were eligible for inclusion in the analyses if they started TNF inhibition for JIA. The primary treatment response was determined 3 to 7 months after start of treatment, based on the JIA American College of Rheumatology Pediatric (ACR Pedi) response criteria, clinical Juvenile Arthritis Disease Activity Score (cJADAS) and persistence of treatment after 6 months. Subsequently, pooled logistic regression models were performed to include long-term follow-up data. The models were adjusted for risk factors associated with poor treatment response. Dosing was expressed by body weight (BW), body surface area (BSA), ideal body weight (IBW), fat free mass (FFM) and lean body mass (LBM). RESULTS: Participants treated with adalimumab (n=328) and etanercept (n=437) were included in the analyses (median dose 0.82 [IQR 0.66-1.04] and 0.83 [IQR 0.75-0.95] mg/kg BW, respectively). The majority of analyses did not show a relationship between dose and outcome. Where associations were found, results were conflicting. Alternative dosing characteristics based on IBW, FFM and LBM did not result in stronger or more consistent associations. CONCLUSION: This study was not able to confirm our hypothesis that increased dosing of TNF inhibitors results in improved treatment outcomes. Although adjustment was performed for risk factors of impaired treatment response, residual confounding by indication likely explains the negative associations found in this study.

Full Text

Duke Authors

Cited Authors

  • Verstegen, RHJ; Shrader, P; Balevic, SJ; Beukelman, T; Correll, C; Dennos, A; Phillips, T; Feldman, BM; CARRA Registry investigators,

Published Date

  • January 18, 2022

Published In

PubMed ID

  • 35040593

Electronic International Standard Serial Number (EISSN)

  • 2151-4658

Digital Object Identifier (DOI)

  • 10.1002/acr.24859

Language

  • eng

Conference Location

  • United States